Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2225-2232

  Thrift, Aaron P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Barrett's Esophagus; Cancer Outcomes; Metformin; NSAIDs; Statins; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ANTIINFLAMMATORY AGENT; HYPOCHOLESTEROLEMIC AGENT;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; COMORBIDITY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HUMAN; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; ADENOCARCINOMA; CHEMOPROPHYLAXIS; COMPLICATION; ESOPHAGEAL NEOPLASMS; MALE; MORTALITY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; SURVIVAL ANALYSIS; UNITED STATES;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; BARRETT ESOPHAGUS; CHEMOPREVENTION; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; PROGNOSIS; PROTON PUMP INHIBITORS; RECURRENCE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84947485458     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.03.028     Document Type: Review

References (113)

1. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. 2013. Available from: Accessed October 22, 2014. http://globocan.iarc.fr.
2. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
3. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
4. Pohl H., Sirovich B., Welch H.G. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 2010, 19:1468-1470.
5. Thrift A.P., Whiteman D.C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012, 23:3155-3162.
6. Vaughan T.L., Fitzgerald R.C. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015, 12:243-248.
7. Engel L.S., Chow W.H., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003, 95:1404-1413.
8. Pandeya N., Olsen C.M., Whiteman D.C. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol 2013, 37:579-584.
9. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2011. National Cancer Institute, Bethesda, MD. Available at: Accessed January 12, 2015. http://seer.cancer.gov/csr/1975_2011/.
10. Cook M.B., Chow W.H., Devesa S.S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009, 101:855-859.
11. Dubecz A., Gall I., Solymosi N., et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012, 7:443-447.
12. Spechler S.J. Clinical practice: Barrett's esophagus. N Engl J Med 2002, 346:836-842.
13. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
14. Kendall B.J., Whiteman D.C. Temporal changes in the endoscopic frequency of new cases of Barrett's esophagus in an Australian health region. Am J Gastroenterol 2006, 101:1178-1182.
15. Spechler S.J., Robbins A.H., Rubins H.B., et al. Adenocarcinoma and Barrett's esophagus: an overrated risk?. Gastroenterology 1984, 87:927-933.
16. Cameron A.J., Ott B.J., Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985, 313:857-859.
17. Corley D.A., Mehtani K., Quesenberry C., et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013, 145:312-319.
18. Bhat S.K., McManus D.T., Coleman H.G., et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 2015, 64:20-25.
19. Whiteman D.C. Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma?. Gut 2015, 64:5-6.
20. Verbeek R.E., Leenders M., Ten Kate F.J., et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol 2014, 109:1215-1222.
21. Sami S.S., Ragunath K., Iyer P.G. Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 2015, 13:623-634.
22. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002, 122:26-33.
23. Corley D.A., Levin T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633-640.
24. Bytzer P., Christensen P.B., Damkier P., et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999, 94:86-91.
25. Cooper G.S., Kou T.D., Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009, 104:1356-1362.
26. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012, 13:518-527.
27. Chan A.T., Detering E. An emerging role for anti-inflammatory agents for chemoprevention. Recent Results Cancer Res 2013, 191:1-5.
28. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
29. Vane J.R., Botting R.M. The mechanism of action of aspirin. Thromb Res 2003, 110:255-258.
30. Wilson K.T., Fu S., Ramanujam K.S., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998, 58:2929-2934.
31. Zimmermann K.C., Sarbia M., Weber A.A., et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
32. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
33. Morris C.D., Armstrong G.R., Bigley G., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
34. Kandil H.M., Tanner G., Smalley W., et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001, 46:785-789.
35. Lagorce C., Paraf F., Vidaud D., et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003, 42:457-465.
36. Taddei A., Fabbroni V., Pini A., et al. Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus. Dig Dis Sci 2014, 59:949-957.
37. Liao L.M., Vaughan T.L., Corley D.A., et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012, 142:442-452.
38. Abnet C.C., Freedman N.D., Kamangar F., et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009, 100:551-557.
39. Anderson L.A., Johnston B.T., Watson R.G., et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006, 66:4975-4982.
40. Thrift A.P., Pandeya N., Smith K.J., et al. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011, 34:1235-1244.
41. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012, 10:722-727.
42. Schneider J.L., Zhao W.K., Corley D.A. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Dig Dis Sci 2015, 60:436-443.
43. Khalaf N., Nguyen T., Ramsey D., et al. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12:1832-1839.
44. Vaughan T.L., Dong L.M., Blount P.L., et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005, 6:945-952.
45. Kastelein F., Spaander M.C., Biermann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141:2000-2008.
46. Heath E.I., Canto M.I., Piantadosi S., et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007, 99:545-557.
47. Falk G.W., Buttar N.S., Foster N.R., et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012, 143:917-926.
48. Das D., Chilton A.P., Jankowski J.A. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009, 181:161-169.
49. Gu Q., Paulose-Ram R., Burt V., et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no 177 2014, National Center for Health Statistics, Hyattsville, MD.
50. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
51. Ogunwobi O.O., Beales I.L. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008, 103:825-837.
52. Sadaria M.R., Reppert A.E., Yu J.A., et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011, 142:1152-1160.
53. Beales I.L., Vardi I., Dearman L., et al. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus 2013, 26:838-846.
54. Alexandre L., Clark A.B., Bhutta H.Y., et al. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology 2014, 146:661-668.
55. Kantor E.D., Onstad L., Blount P.L., et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012, 21:456-461.
56. Beales I.L., Vardi I., Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012, 24:917-923.
57. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
58. Singh S., Singh A.G., Singh P.P., et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:620-629.
59. Nguyen T., Khalaf N., Ramsey D., et al. Statin use is associated with a decreased risk of Barrett's esophagus. Gastroenterology 2014, 147:314-323.
60. Song S., Guha S., Liu K., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56:1512-1521.
61. Kedika R.R., Souza R.F., Spechler S.J. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009, 54:2312-2317.
62. Kastelein F., Spaander M.C., Steyerberg E.W., et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013, 11:382-388.
63. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, 106:1447-1455.
64. Hillman L.C., Chiragakis L., Shadbolt B., et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004, 180:387-391.
65. Nguyen D.M., El-Serag H.B., Henderson L., et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009, 7:1299-1304.
66. de Jonge P.J., Steyerberg E.W., Kuipers E.J., et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006, 101:1421-1429.
67. Singh S., Garg S.K., Singh P.P., et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 2014, 63:1229-1237.
68. Thrift A.P., Shaheen N.J., Gammon M.D., et al. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst 2014, 106:dju252.
69. El-Serag H.B., Hashmi A., Garcia J., et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2014, 63:220-229.
70. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1399-1412.
71. Huang W., Ren H., Ben Q., et al. Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control 2012, 23:263-272.
72. Duggan C., Onstad L., Hardikar S., et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:934-943.
73. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
74. Chak A., Buttar N.S., Foster N.R., et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2015, 13:665-672.
75. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying) - Linked To County Attributes - Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. http://www.seer.cancer.gov.
76. Zell J.A., Ziogas A., Bernstein L., et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009, 115:5662-5671.
77. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
78. Din F.V., Theodoratou E., Farrington S.M., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59:1670-1679.
79. Coghill A.E., Newcomb P.A., Campbell P.T., et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011, 60:491-498.
80. Coghill A.E., Phipps A.I., Bavry A.A., et al. The association between NSAID use and colorectal cancer mortality: results from the women's health initiative. Cancer Epidemiol Biomarkers Prev 2012, 21:1966-1973.
81. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367:1596-1606.
82. McCowan C., Munro A.J., Donnan P.T., et al. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013, 49:1049-1057.
83. Kwan M.L., Habel L.A., Slattery M.L., et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007, 18:613-620.
84. Blair C.K., Sweeney C., Anderson K.E., et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007, 101:191-197.
85. Holmes M.D., Chen W.Y., Li L., et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28:1467-1472.
86. Wernli K.J., Hampton J.M., Trentham-Dietz A., et al. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 2011, 20:131-137.
87. Li Y., Brasky T.M., Nie J., et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2012, 21:239-242.
88. Holmes M.D., Hankinson S.E., Feskanich D., et al. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 2013, 139:507-513.
89. Holmes M.D., Olsson H., Pawitan Y., et al. Aspirin intake and breast cancer survival: a nation-wide study using prospectively recorded data in Sweden. BMC Cancer 2014, 14:391.
90. Murray L.J., Cooper J.A., Hughes C.M., et al. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res 2014, 16:R34.
91. Ratnasinghe L.D., Graubard B.I., Kahle L., et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004, 24:3177-3184.
92. Dhillon P.K., Kenfield S.A., Stampfer M.J., et al. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 2012, 5:1223-1228.
93. Choe K.S., Cowan J.E., Chan J.M., et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012, 30:3540-3544.
94. Flahavan E.M., Bennett K., Sharp L., et al. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 2014, 25:154-159.
95. Grytli H.H., Fagerland M.W., Fossa S.D., et al. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014, 65:635-641.
96. Liu Y., Chen J.Q., Xie L., et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 2014, 12:55.
97. Trivers K.F., De Roos A.J., Gammon M.D., et al. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol 2005, 3:225-230.
98. Thrift A.P., Nagle C.M., Fahey P.P., et al. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control 2012, 23:555-564.
99. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
100. Langevin S.M., Michaud D.S., Marsit C.J., et al. Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013, 22:1061-1068.
101. Lega I.C., Austin P.C., Gruneir A., et al. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013, 36:3018-3026.
102. Bayraktar S., Hernadez-Aya L.F., Lei X., et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012, 118:1202-1211.
103. He X., Esteva F.J., Ensor J., et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012, 23:1771-1780.
104. Lee J.H., Kim T.I., Jeon S.M., et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012, 131:752-759.
105. Kumar S., Meuter A., Thapa P., et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013, 119:555-562.
106. Romero I.L., McCormick A., McEwen K.A., et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012, 119:61-67.
107. Kaushik D., Karnes R.J., Eisenberg M.S., et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014, 32:43.e1-43.e7.
108. Allott E.H., Abern M.R., Gerber L., et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 2013, 16:391-397.
109. Rieken M., Xylinas E., Kluth L., et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 2013, 112:1105-1112.
110. Skinner H.D., McCurdy M.R., Echeverria A.E., et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013, 52:1002-1009.
111. Kobayashi M., Kato K., Iwama H., et al. Antitumor effect of metformin in esophageal cancer: in vitro study. Int J Oncol 2013, 42:517-524.
112. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52.
113. Reid B.J., Li X., Galipeau P.C., et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10:87-101.